Qiagen (NYSE:QGEN) issued an update on its second quarter 2020
IntraDay earnings guidance on Monday morning. The company provided EPS guidance of 0.56-0.56 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.42. The company issued revenue guidance of $443-443 million, compared to the consensus revenue estimate of $417.3 million.Qiagen also updated its FY 2020
Pre-Market guidance to 2.00 EPS.

QGEN stock opened at $45.23 on Tuesday. The stock has a market capitalization of $10.32 billion, a P/E ratio of -282.69, a price-to-earnings-growth ratio of 2.14 and a beta of 0.32. The company has a current ratio of 1.58, a quick ratio of 1.41 and a debt-to-equity ratio of 0.56. Qiagen has a 12 month low of $25.04 and a 12 month high of $45.95. The firm has a 50-day moving average price of $43.36 and a 200-day moving average price of $39.50.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, May 6th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.27 by $0.07. Qiagen had a negative net margin of 2.01% and a positive return on equity of 13.80%. The business had revenue of $372.10 million for the quarter, compared to the consensus estimate of $342.71 million. During the same period last year, the company earned $0.27 EPS. The firm’s revenue was up 6.7% compared to the same quarter last year. As a group, equities analysts predict that Qiagen will post 1.74 EPS for the current fiscal year.

A number of brokerages have commented on QGEN. Warburg Research restated a neutral rating on shares of Qiagen in a research note on Tuesday, June 23rd. Stifel Nicolaus upped their target price on shares of Qiagen from $33.00 to $40.00 and gave the stock a hold rating in a research note on Thursday, April 2nd. DZ Bank reiterated a neutral rating on shares of Qiagen in a research note on Friday, May 29th. Finally, Kepler Capital Markets reiterated a hold rating on shares of Qiagen in a research note on Wednesday, March 25th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and five have given a buy rating to the company. The company has an average rating of Hold and a consensus target price of $37.54.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Featured Story: How Do Mutual Funds Work?

Earnings History and Estimates for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.